• About us
• Contact

Advertisement

Organisation › Details

Janssen Research & Development LLC

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) is part of Johnson & Johnson, the world's most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, New Jersey (USA), and has facilities throughout Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide. *

 

	Start	2012-01-06 renamed before
	Group	Johnson & Johnson (JnJ) (Group)
	Industry	drug discovery
	Industry 2	drug development
	Street	920 Rt 202
	City	08869 Raritan, NJ
		Address record changed: 2020-12-02
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Johnson & Johnson (JnJ) (Group)

• [1] Asgard Therapeutics AB. (3/14/24). "Press Release: Asgard Therapeutics Announces €30 Million Series A Financing to Advance Its First-in-Class in vivo Cell Reprogramming Platform for Immuno-oncology". Lund....
• [2] Evotec SE. (1/26/23). "Press Release: Evotec Announces Agreement with Janssen to Develop Immune-based Therapies". Hamburg....
• [3] Evotec SE. (6/14/22). "Press Release: Evotec Enters a Drug Discovery Collaboration with Janssen". Hamburg....
• [4] Nouscom AG. (5/17/22). "Press Release: Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an ‘Off-The-Shelf’ Cancer Immunotherapy Developed using Nouscom’s Proprietary Viral Vector Platform". Basel....
• [5] GlycoEra AG. (5/3/22). "Press Release: GlycoEra AG Appoints Ganesh V. Kaundinya as President and Chief Executive Officer". Schlieren & Boston, MA....
• [6] VectivBio Holding AG. (4/21/22). "Press Release: VectivBio Appoints Patrick Malloy as Senior Vice President, Investor Relations & Strategic Communications". Basel....
• [7] F-Star Therapeutics Ltd.. (10/20/21). "Press Release: F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics". Cambridge & Cambridge, MA....
• [8] Pureos Partners AG. (9/21/21). "Press Release: Pureos Bioventures Expands the Team by the Appointment of Venture Partners". Pfäffikon....
• [9] Argenx SE. (6/7/21). "Press Release: Argenx to Regain Global Rights to Cusatuzumab". Breda....
• [10] Nouscom AG. (12/11/20). "Press Release: Nouscom Appoints Göran Ando MD as Chairman and Richard Davis PhD as Chief Business Officer". Basel....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.